Announced Date: 2023-05-12 (May 12, 2023)
Asset Name: LM-299
Licensor (Seller): LaNova Medicines (LaNova) (China)
Licensee (Buyer): AstraZeneca
.
Asset Modality: antibody drug conjugate (ADC)
Asset Target: G protein-coupled receptor, class C, group 5, member D (GPRC5D)
Current Stage: pre-clinical stage
Potential Indication: relapsed/refractory multiple myeloma
.
Scope of Authority:
AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305.
.
Payment Detail:
LaNova Medicines is eligible to receive:
Upfront and near-term payments of up to $55 million,
Additional development and commercial milestone payments of up to $545 million,
Total up to $600 million.
Tiered royalties on net sales worldwide.
.
Link:
.
Note:
Chinese Name of “LaNova Medicines“，礼新医药
